2026 Critical Care Congress Skip to main content
2026 Critical Care Congress Main banner
Final Program


Advance Program
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Session Icons
Thought Leader Session
Thought Leader Session
Guidelines Session
Guidelines Session
Aging Adult Track
Aging Adult Track
Additional Registration Fee
Additional Registration Fee

Epidemiology Outcomes
Concurrent

ARDS Subtyping: The Future of Guiding Clinical Intervention

Monday, March 23, 2026
1:30 PM - 2:15 PM Central Time
Location: W181

    Concurrent Session Moderator(s)

  • LE

    Laura Evans, MD, MSc, FCCM

    University of Washington Medical Center, Washington

    Disclosure information not submitted.

Acute respiratory distress syndrome (ARDS) is an acute inflammatory syndrome of the lungs leading to fluid leakage and respiratory failure. Etiologies of ARDS include trauma, inhalation injuries, respiratory infections, and sepsis. In the United States, approximately 10% of ICU patients are thought to have ARDS, with an approximate 40% mortality rate. There are no FDA-approved therapies for ARDS. Clinical management relies on treating the underlying cause and supportive care (e.g., lung ventilation, extracorporeal membrane oxygenation, corticosteroids, fluid management, inflammation reduction). Many drugs have been studied with little success. Clinical failure is thought to be due to ARDS' heterogeneity. Recent research has demonstrated the ability to subtype or endotype patients with ARDS, which could be used to support clinical trials and guide therapies. Speakers will explore some of the research on ARDS subtyping and potential impacts on changing patient prognoses.

Learning Objectives:

  • Explore how biomarkers and clinical features can guide acute respiratory distress syndrome (ARDS) subtypes and endotypes
  • Identify opportunities to leverage ARDS endotypes to inform therapeutic interventions
  • Appreciate the value of both electronic health record integrated algorithms and biomarker data for guiding subtypes or endotypes

Presentations:

  • 1:31 PM - 1:40 PM Central Time
    ARDS Clinical Research: Data Collection Toward Avancing Phenotypes

    Christopher Lindsell, Ph.D (he/him/his)

  • 1:40 PM - 1:50 PM Central Time
    ARDS Precision Medicine

    Michael Matthay (he/him/his)

  • 1:50 PM - 2:00 PM Central Time
    Tools for Precision Therapy for Critical Illness (ARDS, Sepsis): Correlating to Treatment Effect

    Diego A. Rey, PhD – Endpoint Health Inc

  • 2:00 PM - 2:10 PM Central Time
    Type To Treat: BARDA’s Subtyping Program

    Kimberly Sciarretta (she/her/hers)